Holen Sie sich die Stockscreener-App
3.29
2.95%
-0.10
Schlusskurs vom Vortag:
$3.39
Offen:
$3.39
24-Stunden-Volumen:
31,623
Relative Volume:
0.32
Marktkapitalisierung:
$206.46M
Einnahmen:
$3.50M
Nettoeinkommen (Verlust:
$-80.40M
KGV:
-1.2796
EPS:
-2.5711
Netto-Cashflow:
$-29.83M
1W Leistung:
+3.79%
1M Leistung:
-11.56%
6M Leistung:
-25.90%
1J Leistung:
-5.46%
1-Tages-Spanne:
$3.25
$3.39
1-Wochen-Bereich:
$2.96
$3.50
52-Wochen-Spanne:
$2.90
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Firmenname
Camp 4 Therapeutics Corp
Sektor
Branche
Telefon
617-651-8867
Adresse
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
3.29 | 206.46M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
526.51 | 133.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.97B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.88 | 80.20B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
871.08 | 54.78B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.60 | 42.38B | 5.76B | 514.49M | 1.10B | 4.4813 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-15 | Eingeleitet | Needham | Buy |
| 2026-10-05 | Eingeleitet | Oppenheimer | Outperform |
| 2026-06-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2026-06-10 | Eingeleitet | Chardan Capital Markets | Buy |
| 2026-04-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-10-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-27 | Eingeleitet | Wedbush | Outperform |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
| 2022-08-16 | Hochstufung | Craig Hallum | Hold → Buy |
| 2021-12-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2021-09-24 | Bestätigt | Craig Hallum | Buy |
| 2021-06-25 | Bestätigt | Craig Hallum | Buy |
| 2020-12-18 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-04-17 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-05 | Bestätigt | Craig Hallum | Buy |
| 2019-12-20 | Bestätigt | Craig Hallum | Buy |
| 2019-12-20 | Herabstufung | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-01 | Bestätigt | Craig Hallum | Buy |
| 2019-03-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-01-25 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-12-21 | Hochstufung | Craig Hallum | Hold → Buy |
| 2018-12-14 | Bestätigt | B. Riley FBR | Buy |
| 2018-12-11 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | Eingeleitet | Goldman | Neutral |
| 2018-10-15 | Eingeleitet | Jefferies | Hold |
| 2018-09-28 | Bestätigt | Craig Hallum | Hold |
| 2018-04-27 | Bestätigt | Craig Hallum | Hold |
| 2018-03-08 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-02-16 | Hochstufung | First Analysis Sec | Equal-Weight → Overweight |
Alle ansehen
Camp 4 Therapeutics Corp Aktie (CAMP) Neueste Nachrichten
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference - GlobeNewswire Inc.
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference - Yahoo Finance
CAMP4 Therapeutics CorporationCommon Stock (Nasdaq:CAMP) Stock Quote - FinancialContent
Form 8K Camp4 Therapeutics Inc For: 28 September By Investing.com - Investing.com South Africa
Form 8K Camp4 Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Camp4 Therapeutics (Nasdaq:CAMP)Stock Analysis - Simply Wall Street
Form 8K Camp4 Therapeutics Inc For: 28 September By Investing.com - Investing.com UK
CAMP4 receives UK approval for CMP-002 trial sites - grafa.com
CAMP4 Therapeutics Receives MHRA Authorization to Include UK Sites in Global Phase 1/2 Trial of CMP-002 for SYNGAP1-Related Disorder - Quiver Quantitative
CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder - Yahoo Finance
A potential treatment for a genetic disorder is expected to enter human testing late in 2026. CAMP4 will discuss it Sept. 28. - Stock Titan
Camp4 CFO Kelly Gold buys $39,600 in company stock By Investing.com - Investing.com India
Camp4 CFO Kelly Gold buys $39,600 in company stock By Investing.com - Investing.com Canada
Camp4 CFO Kelly Gold buys $39,600 in company stock - investing.com
CAMP4 to Participate in Upcoming Investor Conferences - GlobeNewswire
Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock By Investing.com - Investing.com South Africa
Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock By Investing.com - Investing.com Australia
CAMP4 to Participate in Upcoming Investor Conferences - Yahoo Finance
Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock By Investing.com - Investing.com Nigeria
Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock - investing.com
5AM nears 10% cap in Camp4 Therapeutics (CAMP) while unloading shares - Stock Titan
Camp4 Therapeutics director Andrew Schwab sells $45 in shares By Investing.com - Investing.com Canada
Camp4 Therapeutics Corp presents new approach to treat haploinsufficient diseases via SYNGAP program - Traders Union
Balyasny Asset Management L.P. Reduces Stake in Camp4 Therapeuti - GuruFocus
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock By Investing.com - Investing.com Australia
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock By Investing.com - Investing.com Nigeria
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock By Investing.com - Investing.com South Africa
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock - Investing.com
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock By Investing.com - Investing.com Canada
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock - Investing.com
Camp4 Therapeutics (NASDAQ: CAMP) backer sees stake diluted after new share sales - Stock Titan
Camp4 Therapeutics (NASDAQ: CAMP) insider to sell 1,738 shares - Stock Titan
ETFs Investing in CAMP4 Therapeutics Corporation Stocks - TradingView
Analysts’ Top NA Picks: CAMP4 Therapeutics Corporation (CAMP), Wayfair (W) - The Globe and Mail
CAMP4 Therapeutics (CAMP) Jumps 8% to $4.86: Key Levels to WatchMomentum Stock Picks - vinanet.vn
Balyasny group discloses 4.99% Camp4 Therapeutics (CAMP) position with warrant blocker - Stock Titan
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
CAMP4 Q2 Loss Widens to $33.5M; EPS Misses Estimates - scanx.trade
CAMP4 Therapeutics (Nasdaq: CAMP) widens loss as derivative liability surges - Stock Titan
CAMP4 Therapeutics (CAMP) widens Q2 2026 loss, boosts cash runway to 2028 - Stock Titan
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
Camp4 Therapeutics Corp SEC Filing (Aug 13, 2026) - Stock Titan
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - Yahoo Finance
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Trails Edge reports 6% Camp4 Therapeutics stake (CAMP) totaling 3.79M shares - Stock Titan
CAMP4 Therapeutics Corp expected to post a loss of 21 cents a shareEarnings Preview - TradingView
CAMP Q1 2026 Earnings: EPS Miss Deepens 49.4% as Pre-Revenue Biotech Navigates Pipeline ProgressEarnings Surprise Stocks - vinanet.vn
Camp4 Therapeutics Corp CEO to launch new SYNGAP1 clinical trial in upcoming initiative - Traders Union
Yuri Maricich Acquires 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - MarketBeat
Finanzdaten der Camp 4 Therapeutics Corp-Aktie (CAMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Camp 4 Therapeutics Corp-Aktie (CAMP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 27 '26 |
Sale |
4.04 |
400,000 |
1,616,000 |
2,033,270 |
| Schwab Andrew J. | Director |
Aug 24 '26 |
Sale |
4.50 |
10 |
45 |
2,433,270 |
| Schwab Andrew J. | Director |
Aug 21 '26 |
Sale |
4.50 |
32,018 |
144,081 |
2,433,280 |
| Schwab Andrew J. | Director |
Aug 20 '26 |
Sale |
4.54 |
114,700 |
520,738 |
2,465,298 |
| Tardiff Daniel | Chief Scientific Officer |
Aug 19 '26 |
Sale |
4.76 |
1,738 |
8,273 |
0 |
| Schwab Andrew J. | Director |
Aug 19 '26 |
Sale |
4.76 |
45,147 |
214,900 |
2,579,998 |
| Daniel Tardiff | affiliate |
Aug 19 '26 |
Proposed Sale |
4.76 |
1,738 |
8,276 |
0 |
| Young Richard A | Director |
Aug 03 '26 |
Buy |
1.65 |
16,378 |
27,024 |
186,388 |
| Maricich Yuri | Chief Medical Officer |
Aug 03 '26 |
Buy |
1.65 |
6,551 |
10,809 |
12,611 |
| Gold Kelly | Chief Financial Officer |
Aug 03 '26 |
Buy |
1.65 |
6,551 |
10,809 |
74,428 |
2.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):